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Guanabenz: a centrally acting, natriuretic antihypertensive drug.
Guanabenz is acutely natriuretic and diuretic in saline expanded ani-
mals. In man, guanabenz has not resulted in sodium retention as seen
with other comparable antihypertensives. To directly define the action
of guanabenz on sodium and water excretion in man, we performed
clearance studies during water diuresis on eight hypertensive subjects
under metabolic balance conditions. Each subject underwent three
studies: 1) baseline study: no drug, a water diuresis study; this was
followed by a saline load (=2% BW); 2) acute study (24 hr after
baseline): 16 mg guanabenz P0; and 3) chronic study: after one week of
guanabenz 8 mg P0 BID. In the acute guanabenz studies there were: I)
no changes in GFR or ERPF; 2) an increase in both sodium excretion
and fractional sodium excretion; 3) a rise in free H20 clearance (CH2O)
and (CH,O/GFR) x 100%. These findings were not sustained in the
chronic guanabenz studies. We conclude that in man (preconditioned
with prior saline loading) guanabenz is acutely natriuretic and water
diuretic. These effects are due to decreased tubular sodium and water
reabsorption, probably related to inhibition of alpha adrenergic activity.
The data are consistent with selectively reduced renal sympathetic
activity affecting sodium transport and provide a basis for the absence
of edema and sodium retention associated with guanabenz therapy.
Guanabenz, a centrally acting alpha2-adrenergic agonist, is an
effective antihypertensive agent in man [1]. The mechanism of
action appears to be via central alpha adrenergic stimulation
with suppressed sympathetic outflow to the periphery.
Methyldopa and clonidine, two other centrally acting adre-
nergic agonists, share a similar mechanism of hypotensive
activity. However, the use of these agents is sometimes com-
plicated by salt and water retention which has been reported to
aggravate heart failure, cause edema, and contribute to drug
tolerance [2, 3]. Therefore, it is often necessary to add a diuretic
agent when using these drugs. In contrast to the reported salt
and water retention with methyldopa and clonidine, guanabenz,
administered over a two year period to hundreds of patients in
many centers, has failed to produce a report in which sodium
retention and edema has been attributed to its use [1].
No obvious explanation for this apparent difference between
guanabenz and the older drugs with a similar action has come
forth, but two possibilities are: 1) guanabenz might be a
"purer" alpha2 agonist and therefore have a more selective
action which may not elicit the same type or extent of anti-
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natriuretic response; or 2) guanabenz might have a direct
natriuretic—diuretic effect which counterbalances any tendency
towards sodium retention as a consequence of lowering the
blood pressure.
Regarding the first possible difference, guanabenz appears to
have greater affinity and potency at the alpha2—receptor than a
similar agonist, clonidine [4]. Perhaps this more potent alpha2
agonist activity of guanabenz may directly or indirectly coun-
terbalance any anti—natriuretic stimuli produced by its hypoten-
sive effect.
In regard to the second possible difference, guanabenz has
been shown to promote a moderate diuresis and natriuresis in
hydropenic animal studies. Recent experiments by Strandhoy
et al in the dog [5] and Kauker in the rat [6] have shown that the
acute administration of guanabenz can produce any or all of the
following effects: I) a rise in GFR; 2) an enhanced water
diuresis, presumably secondary to inhibition of vasopressin
secretion and/or blockade of the tubular action of ADH; and 3)
a natriuresis.
On the other hand, previous acute studies in humans have
shown a drop in effective renal plasma flow and glomerular
filtration rate following a single hypotensive dose of guanabenz.
Both anti-diuresis and anti-natriuresis were associated with
these latter hemodynamic changes [8]. However, long—term
guanabenz therapy from one week to six months was not
associated with evidence of altered changes in plasma volume
and renal sodium retention [5, 7—9].
Since previous human clearance studies could not explain the
lack of salt and water retention during chronic administration
and failed to corroborate the natriuresis and diuresis found in
animal studies, we sought a way to promote the expression by
guanabenz of natriuresis and diuresis in man. The modification
employed was the administration of a pre-expanding solution.
According to earlier suggestions by Homer Smith and by Ladd
25 years ago [10, 11], prehydrated normal subjects develop
water diuresis and natriuresis to a subsequent saline load which
is much more exaggerated than the response to saline alone.
These studies demonstrated that man could be preconditioned
such that at a later time (>eight hr) a second natriuretic
stimulus would result in a natriuresis which was of a greater
magnitude than if preconditioning was not performed. "That
the induction of diuresis in prehydrated subjects by isotonic
saline is not attributable to the persistence of excess water in
the body after prehydration is indicated by the fact that if the
interval between prehydration and saline infusion is less than
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eight hr (at a time when the subjects would more likely be
volume expanded) the diuresis is greatly reduced" [10, II]. We
reasoned that by creating a physiological preconditioning, we
might potentiate a natriuresis in response to a second stimulus,
such as altered sympathetic activity, independent of the initial
volume expansion.
We evaluated the effect of guanabenz administered either as
a single dose or after seven days of treatment upon renal
hemodynamics, urine flow and natriuresis. The major modifi-
cation from previous human studies was to administer a modest
saline load 24 hr prior to the acute study.
Methods
Studies were performed in eight male patients with essential
hypertension, aged 31 to 54, who had discontinued all medica-
tion for two weeks prior to the study. The subjects were studied
in the General Clinical Research Center of the University of
Cincinnati.
Each subject was placed on a diet calculated to provide 150
mEq sodium and 50 mEq potassium which was carefully
monitored by pre-meal and post-meal food wt throughout the
study to calculate net quantities consumed. After four days of
dietary stabilization, two 24 hour urine collections were ob-
tained to determine whether the patients were in sodium
balance. The patients then entered into the clearance studies.
Volume and renin studies
After four days of dietary stabilization, an upright plasma
renin level was drawn. In addition, a baseline plasma volume
study was performed. The plasma volume measurement was
repeated after one week of chronic guanabenz administration
for comparison. The patient's wt in kg was measured twice
daily as were the supine and erect blood pressures.
Clearance studies
In each subject, three separate clearance studies were per-
formed in the fasting state with free access to water. The studies
began at 10:00 a.m. and concluded at approximately 2:30 p.m.
The first was a baseline study wherein during an established
steady—state water diuresis, conventional clearance observa-
tions were made. Glomerular filtration rate and effective renal
plasma flow were evaluated using inulin and PAH clearances. A
standard loading dose of inulin and PAH in 5% dextrose and
water was infused over 12 mm followed by a sustaining dose.
After a 50 mm equilibration period, an oral load of tap water, 20
mliter/kg, was given over 20 mm. Spontaneously voided urine
specimens were obtained approximately every eight to 15 mm.
All subjects were supine except to stand for voiding. Urinary
losses were replaced with tap water plus I mliter/min for
insensible losses. Three consecutive timed urine collections
were obtained after the urine flow was stable within 1 mliter/min
for the measurement of flow, sodium, osmolality, inulin and
PAH. Venous blood was collected at the beginning and end of
the study, and at the midpoint of the second collection period,
for the measurement of sodium, osmolality, inulin, and PAH.
At the end of the water diuresis study, the subjects were given
an acute isotonic saline infusion over one hr, equivalent to 2%
body wt, and the study was concluded.
The second phase was performed on the subsequent day
when body wt had returned to baseline and the saline load of the
previous day had been excreted. In this acute study, steady—
state water diuresis was again achieved, and observations were
made within two hr after the administration orally of a 16 mg
dose of guanabenz.
Since in the acute study we were interested in studying the
effect of the anamnestic response to a second natriuretic
stimulus after a prior saline load, we felt it was necessary to
insure that our patients were not volume expanded. Therefore
only patients who had not had a significant wt gain (<0.9 kg)
between the baseline and acute study were included in our
analysis.
Following the acute study, guanabenz was administered in a
dosage of 8mg twice daily for one week; at the end of this time
a chronic study was performed, again during the establishment
of steady—state water diuresis,
Analytical methods
Glomerular filtration rate (GFR) was measured by inulin
clearance and effective renal plasma flow (ERPF) was estimated
by PAH clearance. Inulin in the urine and plasma was deter-
mined by a resorcinal colorimetric technique [12]. PAH was
measured as described by Smith et al [131. The clearance of
PAH (CPAH) and inulin (CIN) were calculated in the usual
manner. Osmolality was measured by the vapor point method
(WescorSlOOB, Logan, Utah, USA). Osmolar clearance (COSM)
was calculated with the following formula:
COSM = UOSM X V/POSM
where UOSM = Osmolality of the urine (mOsm/kg of water),
POSM = osmolality of serum (mOsm/kg of water), and V =
urine flow (mliter/min). Free water clearance (CH,)) was calcu-
lated by the formula CH,O = V — COSM.
Sodium was determined by standard flame photometry (IL
model 143, Lexington, Massachusetts, USA). Plasma renin
activity was determined by an RIA technique [14]. Plasma
volume was measured using a standard radiolabelled albumin
technique (RISA).
Statistical analysis
The mean of three consecutive steady—state clearance peri-
ods in each subject was used as an individual data point. The
data points for the group are reported as mean SEM. Paired
comparisons were made between the baseline study of each
patient to either his acute or chronic study. The significance of
the differences between means was analyzed by Student's t-test
for paired variables after normalizing the data by logarithmic
transformation.
Results
Plasma renin activity, plasma volume, and blood pressure
response
All of the subjects fell into the normal plasma renin group
when factored for urinary sodium excretion, except one who
was in the high renin category.
As shown in Figure 1, blood pressure did not change with
acute guanabenz administration but there was a statistically
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Fig. 1. Data are (mean SEM) from eight subjects (P < 0.03). Upper
end of bar is systolic, lower end is diastolic blood pressure.
significant difference in the diastolic blood pressure after
chronic administration as compared to baseline. In addition,
after one week of guanabenz the plasma volume was not
changed from baseline (baseline: 2282 219 mliter vs. chronic:
2819 279 mliter).
Clearance studies
Table 1 summarizes the effects of acute and chronic
guanabenz administration upon renal hemodynamics, water and
electrolyte excretion. The data are presented as means SEM
during sustained water diuresis under: drug free conditions,
baseline; after 16 mg of guanabenz, acute; and seven days of
guanabenz, chronic.
Renal hemodynamics. There were no significant differences
in either GFR or ERPF between the three experimental phases
(Table 1).
Free water excretion. Data from the three study phases are
summarized in Table I and Figures 2 and 3. Guanabenz acutely
produced a rise in CH2O and V from baseline. Neither CH,o or V
was significantly different from baseline in the chronic study.
The change in CH2O was independent of changes in GFR as
fractional free water clearance (CH2O/GFR x 100) was signifi-
cantly different between baseline and acute, P < 0.02. Frac-
tional CH2O returned to a value not significantly different from
baseline in the chronic phase.
Neither UOSM nor CH2O as a fraction of V were significantly
altered by any of the study conditions.
Sodium excretion (UNOV) and Fractional excretion (FENa)
In every subject there was a rise in UNaV following
guanabenz which varied from 43 to 134% of the baseline values.
(Fig. 4). This was not the result of alterations in the filtered load
but the result of a change in tubular reabsorption of sodium,
since there was a significant change in the fractional excretion
of sodium from baseline to acute, P < 0.02, which returned to
a value not significantly different from baseline in the chronic
phase, (Fig. 5).
Discussion
Our study revealed that guanabenz produced: 1) no signifi-
cant changes in renal hemodynamics; 2) an increase in CH2O
which was unrelated to changes in GFR; 3) an increase in both
absolute and fractional excretion of sodium, suggesting altered
tubular reabsorption. After seven days of guanabenz therapy
there was a significant decrease in diastolic blood pressure. In
addition, the increased excretion of free water and sodium were
not sustained, as both UNaV and CH2O had returned to baseline
levels in the chronic phase.
The results of our acute study seem to be at variance with
other acute studies of guanabenz in some aspects. In our study,
acute guanabenz administration did not change renal hemody-
namics or glomerular filtration rate as compared to reports by
Bauer [8] and Bosanac et al [7]. Part of this difference could
have been due to the apparent lack of an acute effect on mean
systemic blood pressure in the group. However, three subjects
did sustain a fall in blood pressure and despite this there was no
trend towards a decrease in GFR, ERPF, UNaV or CH2O in any
of these subjects.
We feel that a preconditioning saline load could account for
the apparent differences between our observations and those of
other acute studies with guanabenz in two ways. First, as
suggested by Homer Smith [11], prehydration may have pre-
conditioned the subjects to a second natriuretic stimulus (that
is, guanabenz). While the mechanism of preconditioning has not
been elucidated it could be either neural or humoral.
Secondly, it is possible that the stabilization of renal hemo-
dynamics seen in our study may have been related to the
conditioning of prehydration. As suggested by Strandhoy et al
[15], the natriuresis induced by guanabenz can be potentiated
by preventing a significant change in renal hemodynamics,
thereby assuring an adequate filtrate delivery and permitting us
to observe the natriuretic and diuretic effects of guanabenz.
We do not feel that volume expansion from prehydration was
responsible for the natriuresis since the acute studies were
performed after sufficient time to excrete the saline load. Only
subjects whose wt changed less than 0.9 kg from baseline were
included in the analysis. The mean difference in wt was —0.006
0.238 kg. Finally Figure 6 demonstrates that there was no
correlation between the changes in sodium excretion and the
changes in weight from the baseline to the acute study.
Our results are compatable with recently reported animal
studies involving both dogs and rats [5, 61. Strandhoy, Marris,
and Buckalew [5] observed that dogs given guanabenz acutely
exhibited an increase in urine flow and a modest increase in
glomerular filtration rate associated with mild natriuresis. More
recent observations in the dog by this same group revealed that
volume expansion resulted in an enhancement by guanabenz—
induced natriuresis and diuresis [15]. In these latter studies,
volume expansion concomitent with guanabenz markedly in-
creased flow greater than the increase produced by guanabenz
alone. In addition, sodium excretion increased three times as
much when both maneuvers were used together over the
change induced by guanabenz alone. While we did not use a
concomitant saline load to avoid the confounding variable of
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Table I. Acute and chronic effects of guanabenz on renal hemodynamics water and electrolyte excretion
Baseline Acute Chronic
GFR muter/mm 118 10 125 8 115 9
ERPF mliter/min 543 42 522 28 605 43
V muter/mm 12.3 0.9 15.7 l.2*** 11.2 0.7
Uosm mOsm/kg 84 3 83 5 92 7
CH2O
CH2O/GFR x
CH2O/V x 100
UNaV
100
mliter/min
%
%
Eq/min
8.4
7.7
69
205
0.5
1.1
I
48
11.1 l.0**
9.0 0.8*
70 2
429 104**
7.4
6.7
66
162
0.7
0.0
3
89
FENa % 1.49 0.38 2.35 0.45* 1.1 0.2
Symbols are: * P < 0.05; ** P < 0.02; P < 0.01.
Abbreviations are: GFR, glomerular filtration rate; ERPF, effective renal plasma flow; V. urine flow; CH,O, clearance of solute—free water; FEN,
fractional excretion of sodium (%).
volume expansion, our results with guanabenz and a precondi-
tioning saline load in man resemble in some respects the
animals studies, showing as much as a 134% increase in sodium
excretion with a marked rise in V unrelated to any changes in
GFR and ERPF.
Our data suggest, therefore, that in humans guanabenz acutely
inhibits tubular sodium and water reabsorption. The simultaneous
rise in both sodium and free water excretion could be the result of
an increase in proximal filtrate delivery to more distal segments of
the nephron, perhaps related to altered sympathetic activity pro-
duced by guanabenz. Stimulation of alpha adrenergic receptors
which are found in proximity to proximal tubular epithelium
appear to result in enhanced tubular sodium reabsorption.
Guanabenz may have altered sodium transport by decreasing
adrenergic nervous impulses to these receptors.
A
Chronic
Fig. 3. Free water clearance/GFR x 100 (inulin clearance). Data
represent mean SEM. Acute and chronic phases were compared to
baseline, indicates statistically significant difference at the 0.05 level
or better.
Alternatively, guanabenz, by influencing alpha2 agonist ac-
tivity, might have changed salt and water handling in the
nephron as a consequence of altered ADH activity upon tubular
transport. Increased alpha2 adrenergic levels have been shown
to inhibit ADH activity by both a central depression of ADH
release and altered tubular responsiveness to ADH [15, 16, 18].
Evidence regarding the effect upon central ADH release dem-
onstrates that acute guanabenz administration results in de-
creased plasma ADH levels [15]. In addition, several studies
have shown: I) agonist activity at alpha2 receptors reversibly
inhibit the hydroosmotic effect of ADH in the cortical collecting
duct in isolated perfused tubules [17]; 2) guanabenz affects
water flux in response to ADH across toad bladder epithelia, a
transporting epithelium which is similar to the mammalian
collecting ducts [19] and; 3) a diminished capacity to raise Uosm
in response to ADH in dogs given guanabenz [15]. Both the
central and peripheral ADH effects are most likely the conse-
quence of the high affinity and powerful activity of guanabenz
as an alpha2 agonist [4].
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Fig. 2. Free water clearance (CH2O). Data represent mean SEM. Acute
and chronic phases were compared to baseline. * indicates statistically
significant difference at the 0.05 level or better.
7.0
Baseline Acute Chronic
Baseline Acute
1.0 0 1.0 2.0
. Weight, kg
Fig. 6. Data points represent the relationship between the increase in
absolute sodium excretion from baseline to the acute study and the
change in wt between these study days for each subject.
creased, urea recycling would be diminished which would
decrease inner medullary tonicity. Sodium reabsorption in the
thin ascending Loop of Henle would be diminished since it is
passive and depends upon an adequate osmotic gradient [21,
221. If solute delivery out of the proximal tubule was adequate,
the diminished loop sodium reabsorption would result in an
______
increased delivery of sodium and fluid to the distal nephron
r////J.LL_ diluting sites. The overall result of this would be a proportional
increase in both sodium excretion and free water clearance as
seen in our findings. In fact, direct measurements in a dog
model demonstrated that guanabenz significantly depressed
inner medullary solute concentration [15]. Also, micropuncture
studies using another alpha2 agonist, clonidine, in a saline
expanded model revealed an increased delivery of sodium to
the papillary base [23]. Taken together, these results could be
accounted for by a decrease in passive sodium reabsorption by
the thin loops of juxtamedullary nephrons.
Our findings could also be explained as the consequence of
parallel changes in distal reabsorption of sodium and water.
This could account for no net change in Uosm or CH2O/V
(Table 1). Without prior hydration, previous investigators ob-
served an acute fall in renal hemodynamics and GFR with
guanabenz [7, 8]. These changes were associated with a fall in
filtered sodium load and enhanced proximal tubular reabsorp-
tion. Consequently, distal filtrate and sodium delivery could
have been well below the reserve reabsorptive capacity of the
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Fig. 4. Sodium excretion rate (UNV). Data represent mean SEM.
Acute and chronic phases were compared to baseline. * indicates
statistically significant difference at the 0.05 level or better.
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Fig. 5. Fractional sodium excretion (FENd) x 100%. Data represent
mean SEM. Acute and chronic phases were compared to baseline.
* indicates statistically significant difference at the 0.05 level or better.
All studies were performed during steady—state diuresis.
There are at least two possible pathways by which a
guanabenz—induced decrease in ADH activity might influence
sodium reabsorption in the proximal nephron. In some species,
ADH directly increases sodium reabsorption in the thick ascend-
ing limb, and changes in ADH activity produced by guanabenz
could have antagonized this effect [20]. However, this is an
unlikely mechanism for the activity of guanabenz upon sodium
transport since guanabenz does not inhibit ADH-stimulated so-
dium transport in isolated toad bladders, even at a concentration
many thousand times greater than the amount necessary to inhibit
water transport [19].
Alternatively, if ADH activity at the tubule level is de-
1208 Gehr et al
distal nephron. If guanabenz influenced distal nephron thresh-
old reabsorptive capacity, its effect might not have been ob-
served if filtrate delivery were not adequate. However,
prehydration may have conditioned the subjects in some way to
assure adequate delivery to the distal nephron, unmasking a
change in reabsorptive capacity induced by guanabenz.
Experiments involving direct examination of distal tubular
transport as affected by alpha2 agonist drugs have been per-
formed and provide data consistent with the notion that the
collecting duct is the site of tubular inhibition with guanabenz
[6, 24]. Since guanabenz may be affecting both sodium and
water reabsorption in the distal nephron, we are unable to use
the free water clearance technique to calculate either proximal
filtrate delivery or loop reabsorption. Thus we cannot discern
whether our results were the consequence of altered proximal
or distal nephron reabsorption.
When restudied after seven days of guanabenz therapy, all of
the parameters measured had returned to baseline. Thus it
appears that again as in the case with clonidine, certain adaptive
mechanisms are activated to restore the baseline plasma vol-
ume and kidney excretion at a lower blood pressure. We cannot
exclude the possibility that prehydration prior to the chronic
study would have resulted in an increased natriuresis over
baseline. However, as has been observed with other diuretic
antihypertensive agents, the absence of a continued natriuresis
does not result in recurrence of sodium rentention, but merely
reflects the attainment of a new steady—state where anti-
natriuretic and natriuretic forces are balanced. Therefore, the
lack of wt gain and edema seen with guanabenz suggest that the
natriuretic and diuretic properties of this drug adequately
counterbalance the stimulus to salt and water retention coinci-
dent with a fall in blood pressure. We conclude that in some
patients, guanabenz may be used as monotherapy and thereby
improve compliance and avoid the complications of diuretic
therapy.
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